1 T helper lymphocytes that express interleukin-17 (T H 17 cells) have critical roles in mouse models of autoimmunity, and there is mounting evidence that they also influence inflammatory processes in humans. Genome-wide association studies in humans have linked genes involved in T H 17 cell differentiation and function with susceptibility to Crohn's disease, rheumatoid arthritis and psoriasis [1] [2] [3] . Thus, the pathway towards differentiation of T H 17 cells and, perhaps, of related innate lymphoid cells with similar effector functions 4, 5 , is an attractive target for therapeutic applications. Mouse and human T H 17 cells are distinguished by expression of the retinoic acid receptor-related orphan nuclear receptor RORct, which is required for induction of IL-17 transcription and for the manifestation of T H 17-dependent autoimmune disease in mice 6 . By performing a chemical screen with an insect cell-based reporter system, we identified the cardiac glycoside digoxin as a specific inhibitor of RORct transcriptional activity. Digoxin inhibited murine T H 17 cell differentiation without affecting differentiation of other T cell lineages and was effective in delaying the onset and reducing the severity of autoimmune disease in mice. At high concentrations, digoxin is toxic for human cells, but non-toxic synthetic derivatives 20,22-dihydrodigoxin-21,23-diol and digoxin-21-salicylidene specifically inhibited induction of IL-17 in human CD4 1 T cells. Using these small-molecule compounds, we demonstrate that RORct is important for the maintenance of IL-17 expression in mouse and human effector T cells. These data indicate that derivatives of digoxin can be used as chemical templates for the development of RORct-targeted therapeutic agents that attenuate inflammatory lymphocyte function and autoimmune disease.
CD4
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To identify small molecules that specifically inhibit transcriptional activity of RORc and RORct isoforms, we prepared Drosophila S2 cells stably expressing fusions of the GAL4 DNA-binding domain (DBD) and the ligand-binding domains (LBDs) of murine RORc, RORa (mouse homologue of RORc) and DHR3 (Drosophila orthologue for ROR family proteins), as well as the activation domain of the general transcriptional activator VP16. Induction of RORc and the other fusion proteins led to robust expression of a firefly luciferase reporter ( Supplementary Fig. 1a ). Next, we investigated whether RORc activity in the Drosophila system is dependent on a functional LBD and is ligand dependent. A single amino acid change in the putative ligandbinding pocket 7 of RORc completely abrogated its function as a transcriptional activator despite a comparable level of protein expression both in S2 cells and in transgenic fly models ( Supplementary Fig. 1b, c) . In addition, Drosophila cells grown in serum-free media completely lacked RORc activity, unless serum or cholesterol metabolites were supplemented into the cell culture ( Supplementary Fig. 1d ), indicating that yet-to-be-identified ligands are required for RORc reporter activity. These data justify utilization of the heterologous system to identify small molecules that modulate RORc activity.
We next performed a chemical screen with 4,812 compounds and identified digoxin as a specific inhibitor for RORc transcriptional activity (Fig. 1a) . Digoxin inhibited RORc (Fig. 1b and Supplementary Fig. 2a ) with a half-maximum inhibitory concentration (IC 50 ) value of 1.98 mM. Inhibition of RORc activity by digoxin was specific, as there was no effect on the transcriptional activity of VP16 or of the related nuclear hormone receptors RORa and DHR3 (Fig. 1c) . Digoxin did not inhibit the activity of other nuclear hormone receptors, including Caenorhabditis elegans DAF-12, human androgen receptor and LXRa ( Supplementary Fig. 2b, c) . Digitoxin and b-acetyldigoxin also selectively inhibited RORc ( Supplementary Fig. 2d , e) with similar IC 50 values. Next, we examined whether digoxin targets RORc directly. 25-Hydroxycholesterol has been shown to bind to the RORc LBD 8 , and conjugation of fluorescein to this surrogate ligand did not affect its ability to bind to the human RORc LBD (with a dissociation constant (K d ) of 109 nM). Addition of digoxin led to a dose-dependent decrease in fluorescence polarization values, demonstrating that digoxin can displace the sterol ligand with an IC 50 of 4.1 mM (Fig. 1d) . In addition, circular dichroism analysis showed that digoxin increased the thermal stability of the RORc LBD, indicating that it interacts directly with RORc ( Supplementary Fig. 3a ) 9 . Digoxigenin, the aglycone of digoxin, did not inhibit RORct activity in Drosophila cells and did not bind to the RORct LBD in the circular dichroism and competition assays (data not shown and Supplementary Fig. 3b ). We further investigated whether digoxin binds inside the ligand-binding pocket of RORc. We performed random mutagenesis on the LBD and screened 200 clones to identify those that were resistant to digoxin-mediated inhibition. Two clones with this property were identified and shared mutation of amino acid 290 (L290P/A494T and L290F/C318S). RORc harbouring mutations at all three residues (RORc/ct(triple)) exhibited much less sensitivity to digoxin, in spite of transcriptional activity similar to that of the wild-type molecule ( Supplementary Fig. 3c, d) . Two of the mutations mapped to the ligand-binding pocket (L290 and C318) and one to helix 11 (A494) 8 , consistent with digoxin binding inside the pocket.
When naive mouse CD4 1 T cells were cultured under T H 17 polarizing conditions (IL-6 and TGF-b), treatment with digoxin led to markedly reduced expression of IL-17a protein (Fig. 2a) . Transcriptional upregulation of genes encoding the IL-23 receptor (IL-23R), IL-17a, IL-17f or IL-22 was also strongly inhibited ( Supplementary Fig.  4a, b) . Expression of RORct-independent T H 17 signature genes, such as Il21, Maf, Rora, Batf and Irf4, was not affected by digoxin (Supplementary Fig. 4c, d) . Reduction of T H 17 cell differentiation after treatment of wild-type cells with digoxin was similar to that observed upon targeted inactivation of Rorc(ct) (Fig. 2a) . IL-23-induced T H 17 cell differentiation 10 was also inhibited in the presence of digoxin ( Supplementary Fig. 4e ). Importantly, digoxin had no effect on differentiation of naive CD4
1 T cells into other lineages, including T H 1, T H 2 and regulatory T cells ( Supplementary Fig. 4f, g ). Other cardiac glycosides with structures related to digoxin, including proscillaridin A, deslanoside, erysimoside, oleandrin, ouabain, ouabagenin, digitoxigenin, digoxigenin and lanatoside C, had no significant effect on RORc transcriptional activity or T H 17 cell differentiation (Supplementary Fig. 5a , b).
To investigate if RORct is the major target of digoxin or if another dominant cellular target exists, we performed gene expression profiling with total RNA samples isolated from dimethylsulphoxide (DMSO)-or digoxin-treated wild-type or RORct-deficient cells cultured in T H 17 conditions. Treatment with digoxin resulted in changes in gene expression that were very similar to those observed in RORctdeficient cells: two-way ANOVA analysis of differential gene expression revealed 67 genes that were significantly affected by the compound (DMSO versus digoxin) irrespective of genotype (P , 0.05) (Fig. 2b ) and 323 that were affected by the genotype (wild type versus knockout) irrespective of compound treatment (P , 0.05) ( Supplementary Fig.  6a ). Ninety-four per cent of genes affected by digoxin treatment were similarly affected by RORct deficiency. Importantly, no genes were significantly affected by the combination of gene inactivation and digoxin treatment. These results indicate that the effects of digoxin are predominantly mediated through RORct. Induction of RORct messenger RNA and protein expression was not affected by digoxin ( Supplementary Fig. 4a, d ). To rule out the possibility that digoxin mice after transduction with control IRES-GFP (wild type (WT)) or CRE-IRES-GFP (knockout (KO)) retrovirus) activated and expanded in the presence of mouse T H 17 polarizing cytokines. DMSO or 10 mM digoxin was added at 6 h after viral transduction on day 1 and GFP-expressing cells were gated for analysis on day 5. b, Two-dimensional hierarchical clustering of the 67 genes (including redundant probe sets and genes of unknown function) identified to be significantly affected by two-way ANOVA analysis (DMSO versus digoxin treament, P , 0.05). Each row corresponds to a gene and each column corresponds to an experimental sample. c, FACS-sorted naive T cells were transduced with retroviral vectors encoding murine RORa-IRES-GFP or RORct-IRES-GFP on day 1 (16 h after TCR stimulation) and GFP-expressing cells were gated for anyalsis on day 5. DMSO or 10 mM digoxin was added 628 h after transduction. 1 cells) from mice from each group are shown (e). T cells isolated from spinal cords of DMSO (n 5 7) or digoxin treated mice (n 5 7) were stained intracellularly for IFN-c or IL-17a. Statistical analysis was by a two-tailed unpaired Student's t-test; NS, not significant and P 5 0.014 (f).
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blocks steps downstream of RORct activity during T H 17 cell differentiation (for example, IL-17a production), we examined its effect on ectopic expression of RORct or RORa in naive CD4
1 T cells. Both nuclear receptors were previously shown to be sufficient to induce IL-17a expression 11 , presumably by binding to the same cis-acting elements 12 . Digoxin suppressed RORc-and RORct-but not RORamediated induction of IL-17a ( Fig. 2c and Supplementary Fig. 6b ), confirming that it acts selectively on RORct in mouse T cells. However, digoxin (10 mM) failed to inhibit RORct(triple)-mutantmediated IL-17a production ( Supplementary Fig. 3e ). Digitoxin and b-acetyldigoxin also selectively inhibited RORct-dependent T H 17 cell differentiation (Supplementary Fig. 6c ). The aryl hydrocarbon receptor (AhR) is another ligand-dependent transcription factor that augments T H 17 responses 13 . Its activity was unaffected by digoxin, as addition of the AhR ligand 6-formylindolo[3,2-b]carbazole (FICZ) increased RORa-dependent IL-17a expression even in the presence of digoxin (Supplementary Fig. 6d ). RORct is predominantly found in the nucleus of T H 17 cells 14 . Digoxin treatment did not inhibit its nuclear localization in Drosophila cells or in in vitro differentiated T H 17 cells (Supplementary Fig. 7a, b) . These data raise the question of how digoxin suppresses RORct transcriptional activity. Chromatin immunoprecipitation-sequencing (ChIP-Seq) analysis with an anti-RORct antibody ( Supplementary Fig. 7c ) was used for genome-wide identification of its transcriptional target sites in T H 17 cells (M. Ciofani and D.R.L., unpublished results). We evaluated the effect of digoxin on binding of RORct to sites in two relevant loci, Il17a/f and Il23r. RORct binding to these sites was substantially reduced on treatment with digoxin (Supplementary Fig. 7d ), demonstrating one mode of its activity. In vitro, digoxin not only reduced the binding of RORct onto its target, but also displaced SRC3-1b co-activator peptides (IC 50 of 1.8 mM) from the RORct LBD and facilitated its interaction with co-repressor NCOR2 peptides (IC 50 of 3.9 mM) (Supplementary Figs 7e, 8a, b) .
We next examined if digoxin can exert an anti-inflammatory effect in mice. We induced experimental autoimmune encephalomyelitis (EAE)-a T H 17-mediated autoimmune inflammatory disease-in C57BL/6 wild-type mice 15, 16 in conjunction with intraperitoneal (i.p.) injections of digoxin or carrier each day from day 2. Digoxin treatment not only delayed the onset, but also reduced the severity of EAE progression (Fig. 2d) . Also, the total number of mononuclear cells infiltrating the spinal cord was markedly reduced in mice treated with digoxin ( Supplementary Fig. 9 ). Importantly, the percentage of IL-17-producing T cells infiltrating the spinal cord in digoxin-treated mice was reduced by more than 50% as compared to DMSO-treated mice, whereas that of IFN-c-producing T H 1 cells was approximately the same (Fig. 2e, f) . Administration of digoxigenin had no effect on the progression of EAE (data not shown), indicating that the cardiac glycoside activity 17 has no role in the observed amelioration of disease. Digoxin, an inhibitor of the Na 1 /K 1 -ATPase, has long been used for treatment of congestive heart failure 17, 18 , but is toxic for human cells at concentrations (.300 nM) 19 well below those required for RORct inhibition. Expression of the catalytic a1 subunit of murine Na 1 /K 1 -ATPase, which binds digoxin poorly, rendered human cells much less sensitive to digoxin-mediated cytotoxicity 20, 21 . Thus, we ectopically expressed the al subunit of murine Na Fig. 5a, b) , which has inhibitory activity on the Na 1 / K 1 -ATPase similar to digoxin 17 but does not inhibit RORct activity (data not shown), had no effect on IL-17a expression. However, digoxin suppressed IL-17a production ( Supplementary Fig. 10a ). Next, human T cells expressing the murine Na Supplementary Fig.  10b ), demonstrating its direct and selective activity on human RORct.
Cardiac glycosides of the cardenolide class have three common structural motifs, namely a central steroidal core fused with a butenolide and various sugars 23, 24 . The glycans are dispensable, as digoxigenin still inhibits Na Fig. 2d ), which was derived upon butenolide reduction of digoxin by the intestinal commensal Eubacterium lentum 25 , has weak cardiac glycoside activity with much lower binding affinity than that of digoxin for Na 17, 26 , yet it inhibited RORc activity in the S2 reporter system (data not shown). As 20,22-dihydrodigoxin was still cytotoxic for human cells at 2.5 mM, digoxin was further modified by complete reduction of the butenolide to generate 20,22-dihydrodigoxin-21,23-diol (Dig(dhd)) (Fig. 3a) . Dig(dhd) lacked cytotoxic activity on human cells at concentrations up to 40 mM, but it still possessed RORc inhibitory activity and displaced the sterol ligand from the RORc LBD (IC 50 of 12 mM) (Supplementary Fig. 11a ). Additional derivatization of digoxin was achieved by aldol condensation of the butenolide with salicylaldehyde to produce digoxin-21-salicylidene (Dig(sal)) (Fig. 3a) , which, similarly to digoxin, bound directly to RORc in the circular dichroism assay (Supplementary Fig. 3a ). These compounds selectively inhibited both mouse and human RORct activities without affecting those of mouse RORa and human LXRb ( Supplementary Fig. 11b-d) . Moreover, Dig(sal) treatment reduced the severity of EAE progression ( Supplementary Fig. 11e ). When tested on human CD4
1 T cells transduced with viruses encoding RORad or RORct, Dig(dhd) or Dig(sal) treatment selectively suppressed RORct-mediated IL-17a induction ( Supplementary Fig. 11f) . Intriguingly, addition of either compound blocked T H 17 cell differentiation 22 ( Fig. 3b) and induced reciprocal increases of IFN-c or FOXP3 expression in T cells ( Fig. 3b and Supplementary Fig. 11g ), indicating that functional RORct or its ). DMSO, Dig(dhd) or Dig(sal) at indicated concentrations (mM) was added 16 h after cytokine addition.
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downstream events may normally suppress development into other T cell lineages. Expression of another human T H 17 cell-associated surface marker, CCR6, was also reduced in Dig(dhd)-treated cells (Supplementary Fig. 11h) .
We next investigated if digoxin can inhibit IL-17 production from pre-differentiated T H 17 cells. In vitro digoxin treatment of expanded mouse T H 17 cells derived from immunized mice inhibited both IL-23R (Fig. 4a) and IL-17a expression without affecting IFN-c  expression (Fig. 4b) . We also purified GFP-positive T H 17 cells from MOG-immunized Il23r gfp/1 mice 27 after 4-day in vitro culture with IL-23 and MOG peptide. More than 70% of the sorted GFP-positive cells expressed IL-17a ( Supplementary Fig. 12a, day 0) . GFP-positive cells were then treated with DMSO or digoxin for an additional 3 days. Digoxin treatment reduced IL-17a-expressing cells by more than 70% ( Supplementary Fig. 12a, day 3 ), confirming that mouse T H 17 cells generated in vivo and expanded in vitro require continuous RORct activity to maintain their identity. To test if digoxin suppresses the activity of pre-existing T H 17 cells in vivo, we transferred IFN-cdeficient, MBP-specific T H 17 cells into lymphopenic RAG2-deficient mice and assessed EAE manifestation after daily administration of digoxin. Because the transferred cells lack IFN-c, the EAE phenotype observed in these mice is entirely attributable to the function of T H 17 cells. Digoxin treatment from day 2 delayed onset and reduced severity of T H 17 cell transfer-mediated EAE, which further confirms a requirement for continuous RORct activity in T H 17 cells (Supplementary Fig.  12b ). We then examined if RORct activity is also important for sustained expression of IL-17a in human CD4
1 T cells. Human memory T H 17 cells were purified from peripheral blood samples and enriched by in vitro culture. Naive CD4
1 T cells cultured in the same cytokine conditions did not produce IL-17a (Fig. 4c, left plot) . Dig(dhd) treatment led to a 40-50% reduction of IL-17a-expressing cells with little effect on IFN-c-expressing cells (Fig. 4c, d ). These data demonstrate that human RORct activity has an important role in maintaining the human T H 17 cell population.
T cells and innate lymphocytes that produce IL-17a and IL-22 are recognized as having key roles in maintenance of barrier function at mucosal surfaces and also in the pathophysiology of autoimmune disease. All such cells, which include T H 17 cells, other TCRab cells, TCRcd cells, lymphoid tissue inducer cells and NK-like cells (also referred to as NK22 cells) share in the property of requiring expression of RORct for their differentiation. Abrogation of RORct expression results in marked reduction or complete depletion of these cell types and in resistance to T H 17-mediated autoimmune disease in mouse models 4, 6, 28 . Therefore, RORct antagonists digoxin, Dig(dhd) and Dig(sal) may serve as good chemical templates for the development of potent therapeutic compounds to treat various diseases associated with inflammatory lymphocyte dysfunction.
The digitalis-like compounds were originally identified in plants. A body of evidence indicates the presence of endogenous digitalis-like compounds in mammals including humans 18, 29 . Identification of digoxin as a RORct antagonist suggests that related molecules in mammals may modulate RORc-and RORct-mediated functions. However, it would be derivative compounds with better IC 50 values that would have such roles. In light of recent findings of the roles of microbiota in the generation of T H 17 cells in the small intestine 30 , it is interesting that Eubacterium lentum-another commensal bacterium-has the capacity to metabolize digoxin into dihydrodigoxin. The possibility of the existence of endogenous digitalis-like compounds in host organisms and of their modification by microbes may present further opportunities for modulating the function of RORct and T H 17 cell differentiation.
METHODS SUMMARY
Chemical screen. Ten thousand Drosophila stable S2 cells with genomic integration of the Cu 21 -inducible G4DBD-mouse RORc construct were transfected with 5 ng of pUAST firefly luciferase and 7 ng of Pol III Renilla luciferase and dispensed into white-bottom tissue-culture 384-well plates (Corning). Two days later, small compounds (total 4,812 compounds from the ICCB chemical libraries, including Bioactives and Prestwick collections) were added and, after 6 h, Cu 21 was added to the wells (700 mM). The following morning, Stop-glo luciferase substrates (Promega) were used to measure luciferase activity. Initial hits including digoxin were tested against three different control S2 reporter cell lines. Cell culture. Mouse and human CD4 1 T cell culture and viral transduction were performed as described previously 6, 22 , unless indicated otherwise in the text. Identification of non-toxic digoxin derivatives. Various digoxin derivatives were synthesized and first tested for toxicity on human embryonic kidney 293T cells at various concentrations. Compounds exhibiting reduced toxicity compared to digoxin were further tested for their RORc inhibitory activities with the insect cell reporter lines. General. All DNA constructs were generated by PCR-based methodology and confirmed by sequencing. Retroviral production and transduction, EAE experiments and gene chip analysis were performed as described previously 6 . IL-17a, IFN-c, IL-4, FOXP3 and CCR6 protein expression was examined by intracellular or surface staining according to the manufacturer's protocol. LETTER RESEARCH
